You just read:

Clinical Study of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction in Cystoid Macular Edema in Patients Following Cataract Surgery

News provided by

Imprimis Pharmaceuticals , Ahad Mahootchi

12 May, 2016, 08:30 ET